Given its crucial role in cellular immortality, TERT is considered a promising target for cancer therapy. Inhibitors of TERT have been developed and are being tested in preclinical and clinical trials. Histological studies are essential for evaluating the effectiveness of these inhibitors by examining changes in telomere length and cellular proliferation in treated tissues.
